An observational study in Idiopathic Membranous Nephropathy, sponsored by Guangdong Provincial People's Hospital. Terminated at 1 site in China. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-06-18.
Sponsored by Guangdong Provincial People's Hospital · Observational
Idiopathic membranous nephropathy (IMN) remains a common cause of the nephrotic syndrome in adults and one of the leading known causes of end-stage renal disease. Identification of circulating autoantigens provide potential biomarkers for diagnosis and therapy of idiopathic membranous nephropathy. M-type phospholipase A2 receptor (PLA2R) and Thrombospondin type-I domain-containing 7A (THSD7A) were identified as the target antigen in membranous nephropathy with high specificity and the concentration of serum anti-PLA2R antibody and anti-TSHD7A antibody were helpful for predicting disease activity. In our prospective cohort study, hospitalized patients diagnosed as IMN are prospectively studied. Circulating anti-PLA2R antibody and anti-THSD7A antibodies were recently screened by using enzyme-linked sorbent assay(ELISA). This study aims to analyse the difference of clinicopathological characteristics for different concentrations of serum anti PLA2R antibody and anti TSHD7A antibody, and analyze the association between baseline concentrations of serum antibody and disease activity. This study also explored the prediction effects of serum antibody concentrations with different types of therapeutic regimen in IMN and compare the curative effects of different types of therapeutic regimen in different serum antibody concentrations.
119 studies on the registry are indexed under Glomerulonephritis, Membranous; 40 are open to participants now.
This study's enrollment of 85 is below the median of 104 across 33 observational studies indexed under Glomerulonephritis, Membranous.
Browse Glomerulonephritis, Membranous studies →Guangdong Provincial People's Hospital is the lead sponsor of 237 studies on the registry; 102 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients diagnosed with Idiopathic Membranous Nephropathy
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Cyclophosphamide，CTX Determination of serum concentration of anti PLA2R antibody and anti TSHD7A antibody
Diagnostic Test: PLA2R · Diagnostic Test: TSHD7A
Drug: Cyclosporin Determination of serum concentration of anti PLA2R antibody and anti TSHD7A antibody
Diagnostic Test: PLA2R · Diagnostic Test: TSHD7A
Determination of serum concentration of anti PLA2R antibody
Determination of serum concentration of anti TSHD7A antibody
Complete Remission
Urinary protein excretion\<0.3 g/d (uPCR\<300 mg/g or \<30 mg/mmol), confirmed by two values at least 1 week apart, accompanied by a normal serum albumin concentration, and a normal SCr.
Time frame: after treatment for 6 months
Partial Remission
Urinary protein excretion \<3.5 g/d (uPCR \<3500 mg/g or \<350 mg/mmol) and a 50% or greater reduction from peak values;confirmed by two values at least 1 week apart, accompanied by an improvement or normalization of the serum albumin concentration and stable SCr.
Time frame: after treatment for 6 months
estimated Glomerular filtration rate and serum creatinine
time to a 50% reduction in baseline estimated Glomerular filtration rate (according to CK-EPI) and to doubling of baseline creatinine
Time frame: after treatment for 6 months
Plan to share: No
No publications or documents are linked to this record.
This study is terminated, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Glomerulonephritis, Membranous →
Guangdong Provincial People's Hospital →